English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Although for thirty years researchers involved in biomedical investigation have designed international strategies for the protection of the subject of investigation, the consideration of the patient as an active subject in the pharmaceutical business in practice is minimized. One of these compromises in the patient's protection is contained in the Helsinki VI Declaration, in which the laboratory accepts to continue the supply of the medicament and/or method studied postprotocol, when this has been proved to be a benefit to the participant in the research, in practice, this is not fulfilled. Bioethics, as a pro- dialog discipline, tries to approach the involved sectors looking for languages or common points of view in order to have agreements. That is why I, in the present work, used the pharmaceutical laboratory's own arguments, commercial laws and general ethics.

LA CONSIDERACIÓN DEL SUJETO DE INVESTIGACIÓN COMO PARTE ACTIVA EN LA EMPRESA FARMACÉUTICA